BioMarin Pharmaceuticals BMRN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's total equity?
- BioMarin Pharmaceuticals (BMRN) reported total equity of $6.21B in Q1 2026.
- How has BioMarin Pharmaceuticals's total equity changed year-over-year?
- BioMarin Pharmaceuticals's total equity increased by 7.2% year-over-year, from $5.79B to $6.21B.
- What is the long-term trend for BioMarin Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's total equity has grown at a 8.2% compound annual growth rate (CAGR), from $4.1B to $6.09B.
- What does total equity mean?
- The total net value of the company belonging to shareholders.
- How do you interpret total equity?
- An increasing trend generally signals value creation, while a declining trend may indicate persistent losses or excessive share buybacks.
- How does total equity compare across companies?
- Standard metric across all industries; used to calculate Return on Equity (ROE) and book value per share.